Journal profile · Clinical Neurology
Clinical Neuropharmacology
ISSN 0362-5664 · eISSN 1537-162X · Lippincott Williams and Wilkins Ltd. · UNITED STATES · Bimonthly · Founded 1976
Clinical Neuropharmacology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.17; JCR Q4 (journal website); hybrid open access; median 115 days to acceptance (54 articles, last 24 months); community-reported acceptance: fairly easy; 46 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Clinical Neuropharmacology is published by Lippincott Williams and Wilkins Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Parkinson's Disease Mechanisms and Treatments, Neurological disorders and treatments and Epilepsy research and treatment, together about 28.6% of its articles. Its main subfields are Neurology and Psychiatry and Mental health. (generated from OpenAlex topic counts and CAS ranking data)
A ropinirole patch provides continuous dopaminergic stimulation, permitting its increasing use in clinical practice. Inappropriate dose conversion after switching from other dopamine agonists may cause insufficient efficacy or dose-limiting adverse effects. Moreover, factors influencing dose modification remain unclear. Thus, this study aimed to identify factors associated with the need for dose modification in patients with Parkinson disease who switched from another dopamine agonist to a ropinirole patch.
From the journal's Aims & Scope
Research area (LetPub): Clinical Neurology
Editor-in-chief David R. SpiegelPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Parkinson's Disease Mechanisms and TreatmentsMedicine11.6%
- Neurological disorders and treatmentsMedicine9.1%
- Epilepsy research and treatmentMedicine7.9%
- Schizophrenia research and treatmentMedicine7.4%
- Treatment of Major DepressionMedicine6.9%
- Neuroscience and Neuropharmacology ResearchNeuroscience6%
- Pharmacological Effects and Toxicity StudiesMedicine5.8%
- Electroconvulsive Therapy StudiesMedicine4.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Clinical Neurology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Clinical Neurology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Clinical Neurology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: yes
JCR / CiteScore quartiles on the journal's website
- JCR Q4 · CLINICAL NEUROLOGY · rank 250/296
- JCR Q4 · PHARMACOLOGY & PHARMACY · rank 307/356
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.17LetPub ·
- Impact factor (publisher)
- 1.2Publisher website ·
- CiteScore 2026-06
- 2.7LetPub ·
- SJR 2026-06
- 0.42LetPub ·
- SNIP 2026-06
- 0.5LetPub ·
- h-index
- 74LetPub ·
- h-index
- 106OpenAlex ·
- i10-index
- 1,853OpenAlex ·
- 2-year mean citedness
- 1.36OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 6.78%LetPub ·
Volume
- Articles per year
- 36LetPub ·
Articles by year OpenAlex count · 5,020 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 35 | 6 | 9 |
| 2025 | 46 | 3 | 38 |
| 2024 | 40 | 6 | 118 |
| 2023 | 41 | 5 | 189 |
| 2022 | 50 | 8 | 347 |
| 2021 | 61 | 7 | 305 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
115 daysMedian, submission to acceptance · P25–P75 49 days – 187 days
- Acceptance to online
- median 32 days (52 articles)
- Submission to online
- median 154 days
- Sample
- 54 articles with submission and acceptance dates (86 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Lippincott Williams and Wilkins Ltd.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1976
- ISSN
- 0362-5664
- Electronic ISSN
- 1537-162X
- Latest issue on the website
- Volume 49, Issue 4 (August 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Clinical Neuropharmacology
What CAS zone is Clinical Neuropharmacology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Clinical Neuropharmacology is in Zone 4 of Medicine, and in Zone 4 of the minor category Clinical Neurology / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Clinical Neuropharmacology?
The latest impact factor listed by LetPub is 1.17; CiteScore 2.7, h-index 106.
How long does peer review take at Clinical Neuropharmacology?
Based on the dates recorded on 54 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 115 days (interquartile range 49–187 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Clinical Neuropharmacology in?
The journal's website gives JCR Q4; by category, CLINICAL NEUROLOGY Q4 (250/296), PHARMACOLOGY & PHARMACY Q4 (307/356). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 4 of Medicine.
Which databases index Clinical Neuropharmacology?
According to LetPub and DOAJ records, Clinical Neuropharmacology is indexed in SCIE and Scopus.
Is Clinical Neuropharmacology open access, and what is the APC?
Clinical Neuropharmacology is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .